More than 600 patents related to organ-on-a-chip have been filed / granted by industry and non-industry stakeholders, indicating a growing intellectual capital in the domain. More than 600 patent instances, wherein companies as well as academic institutes working in this domain have filed their innovative technologies. Out of all the registered patents, majority (more than 60%) patents have been filed in Asia-Pacific, followed by those filed by World Intellectual Property Organization (18%).
During our research, we came across several partnerships and collaborations that have been established by the players in the organ-on-a-chip domain, with an aim of expanding and diversifying their respective service offerings. As can be observed in the figure, technology / product utilization agreements (24%) emerged as the most popular type of partnership model adopted by players in this domain, followed by product development agreements (19%).
Further, most of the partnerships were inked for multi organ based models (36%), followed by liver based models (19%). It is worth highlighting that the current partnership activity (in terms of number of intercontinental and intracontinental agreements) is concentrated in Europe.
Close to 350 grants have been awarded for ongoing research and development efforts for organ-on-a-chip products and technologies; national center for advancing translational sciences has awarded the maximum grant amount. The Majority (37%) of the total grants in this domain is issued by National Centre for Advancing Translational Sciences. This is followed by the National Heart, Lung, and Blood Institute (14%). Further, it is worth highlighting that currently, majority (10%) of the academic grants in this domain are received by University of California.
Since 2017, over usd 350 million have been invested by several investors across various funding rounds, thereby presenting lucrative growth opportunities within this emerging segment. Players engaged in this domain have raised significant funding through grants and awards amounting to 57% of the total funding instances. This is followed by the number of funding instances in rounds of venture capitals which amounts to 24% of the total funding instances. It is worth noting that in venture capital rounds, most number of funding was observed in venture series A (38%).
Over the past few years, organ-on-a-chip has been proven to transform the current landscape of therapeutic research in the healthcare industry. These models have demonstrated high success rates in various pre-clinical trials resulting in a paradigm shift towards the application of a targeted and a customized approach for modelling a variety of human tissues and diseases.
The forecasted opportunity was analyzed across several relevant parameters, such as type of product (organ based models and disease based models), type of organ (single organ based models and multi organ based models), type of single organ based model (liver based models, lung based models, brain based models, heart based models, intestine based models, kidney based models and other organs based models), type of material of construction (polydimethylsiloxane based models, other polymers based models, glass based models and other materials based models), purpose (research purposes and therapeutic purposes), application area (drug discovery and toxicity testing, cancer research, stem cell research and tissue engineering and regenerative medicines), end user (pharmaceutical and biotech companies, academic and research players, cosmetic industry players and other end users) and geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa).
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Organs-on-Chips Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
Comments
0 comment